{"doi":"10.3389/fonc.2022.858202","title":"Outcomes of Newly Diagnosed Acute Myeloid Leukemia Patients Treated With Hypomethylating Agents With or Without Venetoclax: A Propensity Score-Adjusted Cohort Study","abstract":"There is a deficiency of real-world data on the impact of combining venetoclax (VEN) with hypomethylating agents (HMAs) in newly diagnosed acute myeloid leukemia (AML) patients. We conducted a single-center, propensity-adjusted retrospective cohort study to compare composite complete remission (CCR) rates, median overall survival (m-OS) and median event-free survival (m-EFS). A total of 170 adult AML patients were treated with first-line azacitidine (AZA) or decitabine (DEC) +/- VEN. Median age was 71 years and 99 (58%) were male. Median follow-up in HMA and HMA-VEN groups was 79 and 21 months. Treatments included AZA alone (n=35, 21%), DEC alone (n=84, 49%), AZA-VEN (n=24, 14%) and DEC-VEN (n=27, 16%). VEN improved CCR rates to HMAs overall (52% vs. 27%, P<0.05) and to AZA (54% vs. 10%, P<0.05), but not to DEC (43% vs. 32%, P=0.35); it did not improve OS, and only improved EFS for AZA (10.5 vs. 3.8 months, P<0.05). CCR rates were lower with AZA than with DEC (13% vs. 33%, P<0.05), but OS and EFS were not different statistically. CCR rates did not differ for AZA-VEN vs. DEC-VEN (CCR: 58% vs. 52%, P=0.66), but OS and EFS were longer for AZA-VEN (m-OS: 12.3 vs. 2.2 months, P<0.05; m-EFS: 9.2 vs. 2.1 months, P<0.05). Our analysis showed that combining VEN with AZA in newly diagnosed AML patients improved outcomes, but combining VEN with DEC did not. AZA-VEN was associated with improved outcomes compared to DEC-VEN. Further studies are needed to test the benefit of combining VEN with DEC.","journal":"Frontiers in Oncology","year":2022,"id":256219,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":19,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.868,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2022-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":905089,"name":"Elizabeth M. Corley","orcid":"0000-0002-0077-9750","position":1,"is_corresponding":false},{"id":638754,"name":"Hanan Alharthy","orcid":"0000-0002-9718-084X","position":2,"is_corresponding":false},{"id":905090,"name":"Kathryn Kline","orcid":"0000-0002-1331-9542","position":3,"is_corresponding":false},{"id":638755,"name":"Jennie Y. Law","orcid":"0000-0003-2780-9814","position":4,"is_corresponding":false},{"id":800192,"name":"Seung‐Tae Lee","orcid":"0000-0003-1047-1415","position":5,"is_corresponding":false},{"id":474926,"name":"Sandrine Niyongere","orcid":"0000-0001-9254-0095","position":6,"is_corresponding":false},{"id":771614,"name":"Vu H. Duong","orcid":"0000-0003-0278-7727","position":7,"is_corresponding":false},{"id":233356,"name":"Ashkan Emadi","orcid":"0000-0003-3769-3210","position":8,"is_corresponding":false},{"id":474925,"name":"Maria R. Baer","orcid":"0000-0002-9499-1348","position":9,"is_corresponding":false},{"id":795115,"name":"Moaath K. Mustafa Ali","orcid":"0000-0003-3289-2333","position":0,"is_corresponding":true}],"reference_count":28,"raw_metadata":null,"created_at":"2026-07-19T00:25:21.336200Z","pmid":"35433414","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}